Ixekizumab receives US FDA Approval for the Treatment of Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

US FDA has approved Taltz (ixekizumab) injection for treatment of (nr-axSpA) in patients with objective signs of inflammation. In April 20, the European Committee for Medicinal Products for Human Use recommended approval of ixekizumab for the treatment of adults with nr-axSpA.


Biospace Inc.